HIF-1 mediated activation of antimicrobial peptide LL-37 in type 2 diabetic patients

dc.contributor.authorMohanty S.
dc.contributor.authorKamolvit W.
dc.contributor.authorZambrana S.
dc.contributor.authorGonzales E.
dc.contributor.authorTovi J.
dc.contributor.authorBrismar K.
dc.contributor.authorÖstenson C.G.
dc.contributor.authorBrauner A.
dc.contributor.otherMahidol University
dc.date.accessioned2023-06-18T16:51:06Z
dc.date.available2023-06-18T16:51:06Z
dc.date.issued2022-01-01
dc.description.abstractAbstract: Infections are common in patients with diabetes, but increasing antibiotic resistance hampers successful bacterial clearance and calls for alternative treatment strategies. Hypoxia-inducible factor 1 (HIF-1) is known to influence the innate immune defense and could therefore serve as a possible target. However, the impact of high glucose on HIF-1 has received little attention and merits closer investigation. Here, we show that higher levels of proinflammatory cytokines and CAMP, encoding for the antimicrobial peptide cathelicidin, LL-37, correlate with HIF-1 in type 2 diabetic patients. Chemical activation of HIF-1 further enhanced LL-37, IL-1β, and IL-8 in human uroepithelial cells exposed to high glucose. Moreover, HIF-1 activation of transurethrally infected diabetic mice resulted in lower bacterial load. Drugs activating HIF-1 could therefore in the future potentially have a therapeutic role in clearing bacteria in diabetic patients with infections where antibiotic treatment failed. Key messages: • Mohanty et al. “HIF-1 mediated activation of antimicrobial peptide LL-37 in type 2 diabetic patients.” • Our study highlights induction of the antimicrobial peptide, LL-37, and strengthening of the innate immunity through hypoxia-inducible factor 1 (HIF-1) in diabetes. • Our key observations are: 1. HIF-1 activation increased LL-37 expression in human urothelial cells treated with high glucose. In line with that, we demonstrated that patients with type 2 diabetes living at high altitude had increased levels of the LL-37. 2. HIF-1 activation increased IL-1β and IL-8 in human uroepithelial cells treated with high glucose concentration. 3. Pharmacological activation of HIF-1 decreased bacterial load in the urinary bladder of mice with hereditary diabetes. • We conclude that enhancing HIF-1 may along with antibiotics in the future contribute to the treatment in selected patient groups where traditional therapy is not possible.
dc.identifier.citationJournal of Molecular Medicine Vol.100 No.1 (2022) , 101-113
dc.identifier.doi10.1007/s00109-021-02134-7
dc.identifier.eissn14321440
dc.identifier.issn09462716
dc.identifier.pmid34651203
dc.identifier.scopus2-s2.0-85117052364
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/83951
dc.rights.holderSCOPUS
dc.subjectBiochemistry, Genetics and Molecular Biology
dc.titleHIF-1 mediated activation of antimicrobial peptide LL-37 in type 2 diabetic patients
dc.typeArticle
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85117052364&origin=inward
oaire.citation.endPage113
oaire.citation.issue1
oaire.citation.startPage101
oaire.citation.titleJournal of Molecular Medicine
oaire.citation.volume100
oairecerif.author.affiliationSiriraj Hospital
oairecerif.author.affiliationUniversidad Mayor de San Andres Bolivia
oairecerif.author.affiliationKarolinska Universitetssjukhuset
oairecerif.author.affiliationKarolinska Institutet
oairecerif.author.affiliationCapio Health Care Center

Files

Collections